Preventing Complications in Pregnant Women with Mild and Moderate Severity of Acute Respiratory Infections

• Published in: Èpidemiologiâ i vakcinoprofilaktika (Online) Vol. 17; no. 1; pp. 62 - 73
• Main Authors: Kostinov, M. P., Lukachev, I. V., Meshcheryakova, A. K., Magarshak, O. O., Polischuk, V. B., Faizuloev, E. B., Guseva, T. S., Parshina, O. V., Novikova, S. V., Ignatieva, M. A., Savisko, A. A., Brico, N. I.
• Format: Journal Article
• Language: English; Russian
• Published: Numikom LLC 20.02.2018
• Subjects: беременные; острые респираторные инфекции; рекомбинантныый интерферон-α2b
• ISSN: 2073-3046; 2619-0494
• DOI: 10.31631/2073-3046-2018-17-1-62-73

Relevance. Pregnant women are often exposed to respiratory viruses. Occasionally, the fetus may be harmed by the virus. Goal to present materials revealing the safety and effectiveness of local interferon therapy used in the initial stage of acute respiratory infection in pregnant women from 14 weeks of gestation. Materials and methods. An in-depth analysis of the results of a study of the safety and efficacy of local interferon-therapy of respiratory infections presented in more than 60 literature sources, and own research. Results. It is shown that the inclusion of interferon-α2b (Viferon®) preparation in the complex of basic ARI therapy in pregnant women leads to a decrease in the content in the nasal washout of IL-8, the growth of T-lymphocytes and T-helpers, a more pronounced tendency to decrease natural killers; positively affects the microbiocenosis of the mucous membranes of the upper respiratory tract; leads to a reduction in symptoms of acute pharyngitis, bacterial complications from the upper respiratory tract and, as a consequence, minimizes the need for systemic antibacterial therapy. Conclusions. The conclusion is made about the expediency of including the recombinant interferon-α2b (Viferon®) preparation in intranasal gel form in the complex of basic ARI therapy in pregnant women.